PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2013.19.4.4092013194409HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up dataJeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwonhttp://synapse.koreamed.org/pdf/10.3350/cmh.2013.19.4.409, http://synapse.koreamed.org/DOIx.php?id=10.3350/cmh.2013.19.4.409, http://www.e-cmh.org/upload/pdf/cmh-19-409.pdf
Journal of Hepatology10.1016/s0168-8278(05)81086-4199421S114The follow up of the chronic hepatitis B patients treated with interferon alphahttps://api.elsevier.com/content/article/PII:S0168827805810864?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827805810864?httpAccept=text/plain
Journal of Hepatology10.1016/s0618-8278(19)30488-82019701e258THU-215-Association between core mutations and annual decline rate of HBVDNA and HBsAg in chronic hepatitis B patients treated with nucleoside analogueTakashi Honda, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Mitsuhiro Fujishirohttps://api.elsevier.com/content/article/PII:S0618827819304888?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0618827819304888?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(13)60755-2201358S305753 BASELINE HBsAg PREDICTS HBsAg LOSS AFTER 2 YEARS OF TREATMENT-FREE FOLLOW-UP IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND ADEFOVIRL. Jansen, R.B. Takkenberg, A. de Niet, H.L. Zaaijer, C.J. Weegink, V. Terpstra, M.G.W. Dijkgraaf, R. Molenkamp, P.L.M. Janssen, M. Koot, V. Rijckborst, H.L.A. Janssen, M.G.H.M. Beld, H.W. Reesinkhttps://api.elsevier.com/content/article/PII:S0168827813607552?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S0168827813607552?httpAccept=text/xml
Alimentary Pharmacology & Therapeutics10.1111/apt.151562019497955-955Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? Author’s replyTetsuya Hosakahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.15156, http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15156/fullpdf
Alimentary Pharmacology & Therapeutics10.1111/apt.151432019497954-955Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B?Lung-Yi Makhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.15143, http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15143/fullpdf
Journal of Hepatology10.1016/s0168-8278(09)60916-8200950S332914 HBsAg CLEARENCE AFTER LONG-TERM FOLLOW-UP IN CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALPHA AND NUCLEOS(T)IDE ANALOGUESB. Pinarbasi, S. Kaymakoglu, F. Akyuz, H. Issever, F. Ermis, A. Uyanikoglu, B. Baran, F. Hindilerden, A. Sumnu, K. Demir, F. Besisik, Y. Cakaloglu, Z. Mungan, A. Oktenhttps://api.elsevier.com/content/article/PII:S0168827809609168?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827809609168?httpAccept=text/plain
Journal of Viral Hepatitis10.1111/jvh.57_1242520152249-50P060: Incidence of hepatocellular carcinoma in chronic hepatitis B patients responders to nucleoside analogue treatmenthttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjvh.57_12425
Journal of Hepatology10.1016/s0168-8278(11)60742-3201154S297740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARSP. Marcellin, E.J. Heathcote, M. Buti, Z. Krastev, I. Jacobson, R.A. de Man, G. Dusheiko, S. Zeuzem, C. Barnes, C. Ng, L. Louhttps://api.elsevier.com/content/article/PII:S0168827811607423?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827811607423?httpAccept=text/plain
Journal of Viral Hepatitis10.1111/j.1365-2893.2011.01512.x2011192e97-e104Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-upD. Maruoka, F. Imazeki, M. Arai, T. Kanda, K. Fujiwara, O. Yokosukahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2011.01512.x